Organometallic complexes are an important class of synthetic reagents and are of great interest due to their versatility and wide biological application. The cationic nature of the coordination nucleus facilitates its interaction with biological molecules such as amino acids, proteins, and nucleic acids. The functionalization of peptides or amino acids with organometallic motifs is a novel strategy for the design and development of molecules with greater biological activity, stability in biological environments, and selectivity for specific targets, which make them valuable tools for designing and obtaining molecules with therapeutic applications. The physicochemical properties of ferrocene make it ideal for drug development, due to its structure, stability in aqueous solutions, redox properties, and low toxicity. In the same way, organotin (IV) derivatives have great potential for drug development because of their multiple biological activities, wide structural versatility, high degree of stability, and low toxicity. However, the synthesis of these drugs based on organometallic molecules containing ferrocene or organotin (IV) is quite complex and represents a challenge nowadays; for this reason, it is necessary to design and implement procedures to obtain molecules with a high degree of purity, in sufficient quantities, and at low cost. This review describes the strategies of synthesis used up to now for the preparation of organometallic amino acids and peptides containing ferrocene or organotin (IV) derivates, as well as their impact on the development of therapeutic agents.

有机金属配合物是一类重要的合成试剂，由于它们的多功能性和广泛的生物学应用而倍受关注。配位核的阳离子性质促进其与生物分子（例如氨基酸，蛋白质和核酸）的相互作用。具有有机金属基序的肽或氨基酸的功能化是设计和开发具有更高生物活性，在生物环境中具有稳定性以及对特定靶标具有选择性的分子的新颖策略，这使其成为设计和获得具有治疗用途的分子的有价值的工具。二茂铁的物理化学性质使其结构，在水溶液中的稳定性，氧化还原性质和低毒性使其成为药物开发的理想选择。同样地，有机锡（IV）衍生物具有多种生物活性，广泛的结构通用性，高度的稳定性和低毒性，因此具有开发药物的巨大潜力。然而，基于含有二茂铁或有机锡（IV）的有机金属分子的这些药物的合成是相当复杂的，并且是当今的挑战。由于这个原因，有必要设计和实施程序以足够的数量和低成本获得具有高纯度的分子。这篇综述描述了迄今为止用于制备有机金属氨基酸和含有二茂铁或有机锡（IV）衍生物的肽的合成策略，以及它们对治疗剂开发的影响。基于包含二茂铁或有机锡（IV）的有机金属分子的这些药物的合成非常复杂，代表了当今的挑战；由于这个原因，有必要设计和实施程序以足够的数量和低成本获得具有高纯度的分子。这篇综述描述了迄今为止用于制备有机金属氨基酸和含有二茂铁或有机锡（IV）衍生物的肽的合成策略，以及它们对治疗剂开发的影响。基于包含二茂铁或有机锡（IV）的有机金属分子的这些药物的合成非常复杂，并代表了当今的挑战。由于这个原因，有必要设计和实施程序以足够的数量和低成本获得具有高纯度的分子。这篇综述描述了迄今为止用于制备有机金属氨基酸和含有二茂铁或有机锡（IV）衍生物的肽的合成策略，以及它们对治疗剂开发的影响。